Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2016 June;151(3) > Giornale Italiano di Dermatologia e Venereologia 2016 June;151(3):275-80

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo

 

REVIEWS   

Giornale Italiano di Dermatologia e Venereologia 2016 June;151(3):275-80

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety

Sanja JAVOR, Emanuele COZZANI, Aurora PARODI

DISSAL, Department of Dermatology, IRCCS-AOU S. Martino-IST, University of Genoa, Genoa, Italy


PDF


BACKGROUND: Topical 3% diclofenac in 2.5% hyaluronic acid (HA) gel is a nonsteroidal anti-inflammatory drug approved for the treatment of actinic keratosis (AK). It has been shown to be a safe and effective for treatment of AK on both skin and mucosal lip.
EVIDENCE ACQUISITION: A PubMed search was carried out from 1997 to 2015 using key words in multiple combinations.
EVIDENCE SYNTHESIS: Different studies from the literature shown the efficacy and safety of HA in both immunocompetent and immunosuppressed patients, with important impact on preventing field cancerization. In different clinical trials, the product was effective in significantly reducing lesions when applied for 60 or 90 days.
CONCLUSIONS: Despite the effectiveness of the treatment with topical 3% diclofenac in 2.5% HA, the patients who achieve the complete clinical response should be adequately educated to continue their photoprotection in order to minimize recurrence of AK.

inizio pagina